Physician profile

Otha Myles

Internal Medicine · Overland, MO

NPI 1649379546

$61,063.46

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gilead Sciences, INC. $31,626.08 2019-2022
Pfizer INC. $17,776.99 2019-2022
Viiv Healthcare Company $10,605.50 2019-2021
Janssen Biotech, INC. $234.43 2019-2021
Astrazeneca Pharmaceuticals LP $143.83 2019
Janssen Products, LP $99.99 2019
Merck Sharp & Dohme LLC $82.93 2019
Glaxosmithkline, LLC. $69.43 2019-2021
Janssen Scientific Affairs, LLC $65.12 2019
Astellas Pharma US INC $61.27 2019-2021
Mylan Institutional INC. $43.92 2019
Napo Pharmaceuticals INC $36.85 2020
Tetraphase Pharmaceuticals, INC. $35.25 2019
Abbvie INC. $29.99 2019-2021
Novo Nordisk INC $27.91 2021
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Allergan, INC. $25.96 2019
Lilly USA, LLC $20.45 2019
Emd Serono, INC. $19.98 2021
Amarin Pharma, INC. $16.05 2020
Otsuka America Pharmaceutical, INC. $15.23 2019
E.R. Squibb & Sons, L.L.C. $14.71 2019
Cumberland Pharmaceuticals, INC. $11.59 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Otha Myles

$61,063.46

in general payments reported 2019-2025

Years
2019-2022
Top company
Gilead Sciences, INC.

https://glasscript.com/doctor/165266/otha-myles

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.